| Background and objective:CHF is an extremely common and serious clinical cardiovascular disease symptom complex, which is the serious or the end stage of all kinds of heart disease. CHF is a disord with high mutilation rate and lethality rate, which is jeopardizing the people's health seriously. The mechanisms and therapy of CHF has been a matter of great interest in both clinical and experimental settings. Qiliqiangxin is an effective traditional Chinese medicine compound prescription preparation which has been used on CHF patients for many years and is depending on the basic law which is tonifying pneuma, warmingyang, promoting blood flow and using diuretic of gydragogue to alleviate water retention. But the modern pharmacology mechanism of treatmenting chronic heart failure is still not so clear. In this experimental study, The experiments were carried out about the effects on the indexes of hemodynamies,left ventricle mass index and and heart mass index,the express of Bax and Bcl-2 of CHF rats to discuss its function mechanism initially, provide the science theory basis for the clinical medication.Methods:120 SD rats were tested as subjects and the model rats were built by anterior descending coronary deligation ,then the survival 90 rats were devided into 6 groups randomly. There were 15 rats in every group. They are sham operated group, model group, treating group(Qiliqiangxin with great dosage, medium dosage, small dosage) and contrasting group(captopril group).One week later, sham operated group and model group were given distilled water, treating group were given Qiliqiangxin, the contrasting group was given captopril. After 4 weeks, all rats'heart function were measruated by right flank arteria carotis communis arterial cannula., the left ventricle mass index was calculated and the expression of protein Bax and Bcl-2 was tested by immunohistochemical method to assess the effect of qiliqiangxin.Results:1. Compared with the sham group, model group rats had significantly increased LVEDP and declined LVSP,+ dp / dtmax,-dp/dtmax(P <0.01). The treatment group rats can increase LVSP, lower LVEDP, + dp / dtmax, -dp/dtmax compared with the model group; The great dosage group and medium dosage is better than small dosage Group and the captopril group(P <0.05, or P <0.01), but there was no significant difference between them( P> 0.05).2. Compared with the sham group, model group rats had significantly increased HMI, LVMI significantly(p <0.01); Compared with the model group, HMI, LVMI decreased significantly in great dosage group and medium dosage and captopril group rats, the difference is was significant (p<0.01), but there was no significant difference between them(P> 0.05).3. Compared with the sham group ,the rate of Bcl-2/Bax declined in model group rats(P <0.01). The treat group can raise Bcl-2/Bax in CHF rats (P <0.05, or P <0.01), the great dosage, medium dosage,and captopril group is better than small dosage group, but there is no significant difference between them(P> 0.05).Conclusion:Qiliqiangxin can improving cardiac function through improving the CHF rat's indexes of hemodynamies; It can reduce the left ventricle mass index and heart mass index; It can reduce the express level of Bax and increase the express level of Bcl-2, to increase the rate of Bcl-2/Bax. This experiment has provided the objective basis for the clinical practice that Qiliqiangxin is an effective medicine for CHF which is worth further studying.
|
PDF Full Text Request